HLA-A24 and survivin: possibilities in therapeutic vaccination against cancer
<p>Abstract</p> <p>Recently, it was described that an HLA-A24 restricted peptide derived from the survivin splice variant survivin-2B can be recognized by CD8(+) cytotoxic T-cells. The identification of an HLA-A24 epitope is critical for survivin-based immunotherapy as HLA-24 is th...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2006-09-01
|
| Series: | Journal of Translational Medicine |
| Online Access: | http://www.translational-medicine.com/content/4/1/38 |